Arexvy clinical trials

Studies by the year they started

19 studies that test it; most in 2024 (7)

Who runs them

Industry 16 · Other 3

GlaxoSmithKline (16) · University Health Network, Toronto (1) · Johns Hopkins University (1) · Medical University of Vienna (1)

Often tested with

Tested in the same studies.

mRNA COVID-19 Vaccine (1) · Pneumococcal 20-Valent Conjugate Vaccine (1) · Shingrix (1) · Injectable Suspension Dosage Form (1)

Studies

Open first, then newest update. How each study uses arexvy is read from its arms, and is right about nine times in ten.

Testing it · 19

• Immunogenicity of RSVPreF3 Vaccine in Immunocompromised PersonsRecruitingPhase 2Johns Hopkins UniversityNCT07050732Written as Arexvy (2 doses total)
• RSV Vaccination in Immunocompromised Patients.RecruitingPhase 2Medical University of ViennaNCT06597916Written as Arexvy powder and suspension for injection
• An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyActive, not recruitingPhase 3GlaxoSmithKlineNCT06534892Written as RSVPreF3 OA vaccine
• Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AboveActive, not recruitingPhase 3GlaxoSmithKlineNCT04732871Written as RSVPreF3 OA investigational vaccine
• A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseActive, not recruitingPhase 3GlaxoSmithKlineNCT07220109Written as RSVPreF3 OA vaccine
• A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)CompletedPhase 3GlaxoSmithKlineNCT06614725Written as RSVPreF3 OA investigational vaccine
• A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and AboveCompletedPhase 2GlaxoSmithKlineNCT05921903Written as RSVPreF3 OA Investigational Vaccine
• A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and OlderCompletedPhase 3GlaxoSmithKlineNCT06551181Written as RSVPreF3 OA investigational vaccine
• RSV Vaccine in Transplant RecipientsActive, not recruitingPhase 3University Health Network, TorontoNCT06593210Written as Adjuvant, non-live RSV vaccine
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT06374394Written as RSVPreF3 OA investigational vaccine
• A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and AboveCompletedPhase 3GlaxoSmithKlineNCT06389487Written as RSVPreF3 OA investigational vaccine
• Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT04886596Written as RSVPreF3 OA vaccine
• Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older AdultsCompletedPhase 3GlaxoSmithKlineNCT05879107Written as RSVPreF3 OA investigational vaccine
• A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy AdultsCompletedPhase 3GlaxoSmithKlineNCT05966090Written as RSVPreF3 OA investigational vaccine
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and AboveCompletedPhase 3GlaxoSmithKlineNCT05590403Written as RSVPreF3 OA investigational vaccine
• A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT05559476Written as RSVPreF3 OA investigational vaccine
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT05568797Written as RSVPreF3 OA vaccine
• A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT04841577Written as RSVPreF3 OA investigational vaccine
• A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT05059301Written as RSVPreF3 OA investigational vaccine